

Evaluation of Fluticasone Propionate Aqueous Nasal Spray Taken Alone and in Combination with Cetirizine in the Prophylactic Treatment of Seasonal Allergic Rhinitis

C. Benincasa¹ and R.S. Lloyd²

¹ Allen and Hanburys Ltd, Uxbridge, Middlesex, England

² Weeping Cross Surgery, Stafford, England

Summary

This was a multicentre, double-blind study in 454 patients to compare the effectiveness and tolerability of fluticasone propionate nasal spray (FPANS) 200µg used once daily for 8 weeks on its own or in combination with oral cetirizine 10mg once daily in the treatment of seasonal allergic rhinitis. The results showed no significant difference between treatments in any of the symptoms or in the proportion of symptom-free days. Watery eyes were recorded as being the most troublesome symptom in the previous hayfever season, whilst during the study patients were, on average, free of eye symptoms for 56% of the time. Additionally, no difference was detected between the two groups with regard to the use of rescue medication. More than 75% of patients concluded at the end of the study that their symptoms had been adequately controlled and, similarly, investigators rated both treatments as being successful for the majority of patients. Overall, this study suggests that there is no significant difference in efficacy between FPANS 200µg, taken once daily in the morning, and FPANS 200µg once daily in combination with oral cetirizine 10mg, in the prophylactic treatment of seasonal allergic rhinitis.

Seasonal allergic rhinitis (SAR), defined as a noninfectious inflammatory reaction of the nasal mucosa to allergens such as pollen from grasses and trees, clinically presents with symptoms ranging from uncomfortable nasal congestion, chronic or recurrent sneezing and rhinorrhoea, to headache

and cough. Additionally, some patients complain of nasal itching, eye irritation, and wheeziness (seasonal allergic asthma).^[1,2] The pathogenesis of seasonal allergic rhinitis is believed to involve immediate type 1 allergic reactions with diagnosis confirmed by the 'skin prick test' if necessary.

The prevalence of the condition in the UK population ranges from 10 to 15%, with the incidence apparently increasing, possibly due to pollution.^[3] The hayfever season in the UK starts in about March (tree pollination), continues through June and July (grass pollination), and ends in August after weed pollination, although some sensitivity to mould spores can occur in August or September.^[3]

There are several approaches to the treatment of seasonal allergic rhinitis, including avoidance of the appropriate allergy, topical nasal sprays or eye drops, and systemic therapies.^[4] For the past 20 years, topical corticosteroids have been used successfully in the treatment of allergic rhinitis. These drugs have vasoconstrictor and anti-inflammatory properties that alleviate the symptoms of rhinitis. Fluticasone propionate nasal spray (FPANS) is a recent addition to the currently available topical corticosteroids, which, at a once-daily dose of 200µg, has been shown to be highly effective in the treatment of allergic rhinitis^[5] and equivalent in efficacy to that of other comparator topical corticosteroids (intranasal beclomethasone dipropionate 168µg twice daily^[6,7] and flunisolide 100µg twice daily^[8]). Furthermore, FPANS possesses 2 distinct advantages over other topically active corticosteroids: (a) being effective as a once-daily dosage, the drug may act as an aid to patient compliance,^[9] and (b) it has extremely low oral bioavailability^[10] and therefore a low potential to produce unwanted systemic side effects. This lack of systemic activity has been demonstrated in healthy volunteers taking either high oral doses of fluticasone propionate^[10,11] or high intranasal doses^[10] over a period of several days.

Systemic antihistamines have also been used as a treatment for SAR, with the original histamine H₁-receptor antagonists now being replaced by second generation nonsedative drugs in this class.^[4] Cetirizine dihydrochloride is an antihistamine in this group that has been shown to be effective in controlling the symptoms of hayfever at a once-daily dosage of 10mg.^[12] Furthermore, it has been shown to produce a significant improvement in eye irritation and watering.^[12] While intranasal

corticosteroid therapy is highly effective in reducing the nasal symptoms associated with seasonal allergic rhinitis, it may be less effective in controlling eye symptoms.^[13] In a recent study in which loratidine and beclomethasone dipropionate were used in combination, there was some evidence that overall control of symptoms improved.^[14]

This study aimed to evaluate the efficacy and safety of FPANS 200µg once daily, taken alone and in combination with one tablet of cetirizine dihydrochloride 10mg, in the treatment of seasonal allergic rhinitis.

Patients and Methods

Patients

Patients eligible to take part in this study were males or females aged over 12 years who had required treatment for the symptoms of hayfever during the month of June in the 2 previous years. Patients must have had at least two of the following symptoms, one of which should have been a nasal symptom: sneezing, nasal itching, runny nose, nasal congestion, eye watering/irritation and headache. Patients were to remain in their usual environment throughout the study.

Patients not eligible were those who had received a prescription medicine for the treatment of an upper or lower respiratory tract infection within the previous 2 weeks, or had received treatment for allergic rhinitis within the last week. Any patients who had received intranasal corticosteroids or oral corticosteroids within the previous 4 weeks were also excluded, as were those who had received ketotifen or sodium cromoglycate in the same time period. Patients taking astemizole within the previous 6 weeks, depot corticosteroids within 8 weeks, or receiving desensitisation injections to grass pollen in the previous 6 months were also excluded.

Additional exclusion criteria included: nasal surgery in the previous 2 months, nasal infections or significant nasal pathology (polyps, septal deviation, hypertrophy of turbinates), chronic infective rhinosinusitis, serious concomitant disease, treat-

Table I. Patient characteristics (total study population)

	No. of patients (%)	
	FPANS alone	FPANS plus cetirizine
Total no. of patients	227	227
Males	95 (42)	99 (44)
Females	132 (58)	128 (56)
Mean age (years) [range]	31 [12-80]	30 [12-66]
Duration of seasonal allergic rhinitis		
<10y	104 (46)	109 (48)
>10y	123 (54)	118 (52)
Severity of seasonal allergic rhinitis		
Mild	21 (9)	12 (5)
Moderate	160 (70)	162 (71)
Severe	46 (20)	53 (23)
Hayfever symptoms of previous year		
Headache	81 (36)	98 (43)
Sneezing	216 (95)	216 (95)
Watering eyes	207 (91)	201 (89)
Most troublesome symptom last year		
Watering eyes	108 (48)	126 (56)
Most widely used medications		
Antihistamines (49% of all medications)	169 (74)	176 (78)
Corticosteroids (29% of all medications)	108 (48)	97 (43)

Abbreviations: FPANS = fluticasone propionate aqueous nasal spray 200µg once daily in the morning; FPANS plus cetirizine = fluticasone propionate aqueous nasal spray 200µg once daily in the morning plus one tablet of cetirizine 10mg.

ment with concomitant medication likely to interfere with the efficacy of the study medication, recurrent conjunctivitis, the wearing of soft contact lenses, and pregnancy or lactation. Women of childbearing potential were only included if the investigator considered that they were taking adequate contraceptive precautions.

Finally, patients with asthma were eligible for entry into the study provided that they were unlikely to require a change in medication over the 8-week study period.

All patients were required to give their written informed consent before participating in the study, with those under the age of 16 years providing the consent of a parent or legal guardian. The study was approved by one local Ethics Committee on behalf of all participating centres.

Design

This was a double-blind, multicentre, parallel group study carried out amongst general practice patients in the UK. Eligible patients were randomly assigned to one of two treatment groups; either FPANS 200µg once daily (2 actuations per nostril) in the morning plus 1 placebo tablet, or FPANS 200µg once daily in the morning plus one cetirizine 10mg tablet. Medication was taken for 8 weeks starting on 14 May, 1990, to ensure that treatment was commenced before the beginning of the expected hayfever season in the UK. Patients were also provided with eye drops containing a mixture of antazoline and xylometazoline (Otrivine-Antistin®, Ciba Vision) to be used if eye symptoms became troublesome.

Table II. Mean symptom scores^a for the total population

	FPANS alone	FPANS plus cetirizine	95% Confidence interval
Total no. of patients	227	227	
Nasal symptoms			
Mean	1.5	1.5	-0.3 to 0.3
SD	1.4	1.6	
Range	0.0 to 7.1	0.0 to 8.4	
(Missing)	(30)	(29)	
Eye symptoms			
Mean	1.3	1.1	-0.1 to 0.4
SD	1.3	1.3	
Range	0.0 to 6.2	0.0 to 7.3	
(Missing)	(30)	(30)	
Headache			
Mean	0.4	0.4	-0.1 to 0.2
SD	0.9	0.7	
Range	0.0 to 6.0	0.0 to 4.0	
(Missing)	(30)	(31)	

a Symptoms were rated on a 10-point scale: 0 = absent to 9 = very severe.

Abbreviations: FPANS = fluticasone propionate aqueous nasal spray 200µg once daily in the morning; FPANS plus cetirizine = fluticasone propionate aqueous nasal spray 200µg once daily in the morning plus one tablet of cetirizine 10mg.

Table III. Proportion of symptom-free days^a for the total population

	FPANS alone	FPANS plus cetirizine	95% Confidence interval
Total no. of patients	227	227	
Nasal symptoms			
Mean	0.45	0.46	-0.08 to 0.07
SD	0.38	0.4	
Range	0.0 to 1.0	0.0 to 1.0	
(Missing)	(30)	(29)	
Eye symptoms			
Mean	0.56	0.57	-0.09 to 0.05
SD	0.36	0.36	
Range	0.0 to 1.0	0.0 to 1.0	
(Missing)	(30)	(30)	
Headache			
Mean	0.86	0.85	-0.03 to 0.06
SD	0.22	0.25	
Range	0.0 to 1.0	0.0 to 1.0	
(Missing)	(30)	(31)	

a A score of 0 represents no days symptom-free, a score of 1 indicates that all days were symptom-free.

Abbreviations: FPANS = fluticasone propionate aqueous nasal spray 200µg once daily in the morning; FPANS plus cetirizine = fluticasone propionate aqueous nasal spray 200µg once daily in the morning plus one tablet of cetirizine 10mg.

Table IV. Proportion of days for which rescue medication^a was not taken (total study population)

	FPANS alone	FPANS plus cetirizine	99% Confidence interval
Total no. of patients	227	227	
Mean	0.81	0.82	-0.05 to 0.10
SD	0.29	0.26	
Range	0.00 to 1.0	0.00 to 1.0	
(Missing)	(48)	(54)	

a A score of 0 indicates rescue medication was required, a score of 1 indicates medication was not required every day.

Abbreviations: FPANS = fluticasone propionate aqueous nasal spray 200µg once daily in the morning; FPANS plus cetirizine = fluticasone propionate aqueous nasal spray 200µg once daily in the morning plus one tablet of cetirizine 10mg.

Methods

At the initial clinic visit, investigators recorded demographic details for each patient together with a brief clinical history and an assessment of the severity of symptoms during the hayfever season of the previous year and the medication taken.

Patients were reassessed at clinic visits following 3 and 8 weeks' treatment.

Patients were issued with a daily diary card on which to record scores for their nasal and eye symptoms, and headache. These symptoms were scored on a 10-point categorical rating scale, where 0 = no symptoms, 1-3 = mild symptoms, 4-6 = moderate symptoms, and 7-9 = severe symptoms. Additionally, patients were asked to record their use of study medication, eye drops, and any other concurrent medication.

At the end of the study, patients were asked whether or not they felt that study medication had adequately controlled nasal and eye symptoms and

headache. The investigator was also asked to assess the measure of success of the study treatment in controlling the symptoms of seasonal allergic rhinitis.

Analysis

Symptoms (nasal symptoms, eye symptoms and headache) collected in the daily diary cards for weeks 3 to 8 inclusive (the period during which pollen count was the highest) were used in the assessment of symptom scores and symptom-free days. Treatment groups were compared for all measures of efficacy using a normal test; confidence intervals, 95% (symptoms) or 99% (use of rescue medication and overall assessments), were calculated using the appropriate standard error.

For the analysis of the proportion of symptom-free days and daily symptom scores, p values ≤0.05 were considered to indicate a statistically significant result. For the analysis of the proportion of days free of relief medication and patient's and physician's assessment scores, p values ≤0.01 were considered to indicate a statistically significant result.

Results were analysed before and after excluding patients who violated the study protocol, and as the outcome of these analyses were similar, data collected for the total (intention-to-treat) population are presented in this paper.

Table V. Percentage of patients reporting adequate control of symptoms

	FPANS alone (n = 227)	FPANS plus cetirizine (n = 227)
Nasal symptoms	88%	89%
Eye symptoms	75%	82%
Headache	83%	86%

Abbreviations: FPANS = fluticasone propionate aqueous nasal spray 200µg once daily in the morning; FPANS plus cetirizine = fluticasone propionate aqueous nasal spray 200µg once daily in the morning plus one tablet of cetirizine 10mg.

Adverse Events

Reports of adverse events were summarised as either serious (including anything requiring withdrawal from the study) or minor, and tabulated.

For the purpose of this study, a minor adverse event included events/symptoms requiring treatment, and therefore included reports of events/symptoms that were attributable to either seasonal allergic rhinitis or the use of other antihistamines. Serious adverse events were defined as life-threatening events, death, events requiring or prolonging hospitalisation, events that were disabling or incapacitating, congenital anomaly, cancer or drug overdose, or clinical or laboratory events leading to drug withdrawal.

Results

Study Population

A total of 455 patients drawn from 64 general practices in the UK entered the study. One patient withdrew before the study medication was given and was not assigned to any treatment group. 227 patients were allocated to each of the 2 treatment

Table VI. Serious adverse event reports (total study population)

	FPANS alone (n = 227)	FPANS plus cetirizine (n = 227)
Total number of reports	12 (5%)	10 (4%)
Drowsiness/tiredness/lethargy	2	3
Dizziness/nausea	1	0
Headache	1	1
Exacerbation of rhinitis	1	2
Chest infection	1	0
Nasal condition	2	0
Epistaxis	0	1
Shortness of breath	0	1
Eye disorders	1	1
Allergic rash	1	0
Pain in joints	1	0
Pregnancy	1	0
Ear disorders	0	1

Abbreviations: FPANS = fluticasone propionate aqueous nasal spray 200µg once daily in the morning; FPANS plus cetirizine = fluticasone propionate aqueous nasal spray 200µg once daily in the morning plus one tablet of cetirizine 10mg.

Table VII. Most commonly reported minor adverse events

Adverse event	FPANS alone [no. of reports (% of total)]	FPANS plus cetirizine [no. of reports (% of total)]
Headache	82 (28)	64 (22)
Tiredness	6 (2)	14 (5)
Tension headache	10 (3)	12 (4)
Drowsiness/lethargy/ sleepiness	10 (3)	11 (4)
Acute nasopharyngitis	12 (4)	12 (4)
Sore throat	6 (1)	12 (4)
Epistaxis	8 (3)	12 (4)
Eye disorders	13 (4)	9 (3)
Exacerbation of rhinitis	10 (3)	7 (2)
Upper respiratory tract infection	8 (3)	9 (3)

Abbreviations: FPANS = fluticasone propionate aqueous nasal spray 200µg once daily in the morning; FPANS plus cetirizine = fluticasone propionate aqueous nasal spray 200µg once daily in the morning plus one tablet of cetirizine 10mg.

groups, and their demographic details are summarised in table I.

The treatment groups were well balanced with respect to age, gender, and severity and duration of seasonal allergic rhinitis, with the majority of patients in each group having a history of moderate or severe seasonal allergic rhinitis for more than 10 years.

During the hayfever season of the previous year, most patients in both groups had experienced nasal and eye symptoms, watering eyes being the most troublesome symptom. Previous use of medication for rhinitis was similar in the 2 groups (table I).

Symptoms

There were no significant differences between treatments at the 5% level in any of the symptoms or in the proportion of symptom-free days (tables II and III). All mean symptom scores were low, indicating that both treatments were successful in controlling the symptoms of seasonal allergic rhinitis. An analysis of the proportion of symptom-free days in the 6-week analysis period showed that, on average, patients were free of nasal symptoms for 45% of the time, eye symptoms for 56% of the time, and headache for 85% of the time.

Use of Rescue Medication

The proportion of days for which rescue medication (i.e. antazoline-xylometazoline eye drops) was not required was calculated over the 6-week analysis period. There was no evidence of any difference between treatments, with all patients requiring extra eye medication on approximately 20% of the days (table IV).

Overall Assessments

At the end of the study, patients were asked whether the study treatment had adequately controlled their nasal, eye and headache symptoms, and their responses are summarised in table V. A high proportion of patients in both treatment groups (>75%) found that all symptoms were adequately controlled.

The investigator was asked to determine the success or failure of treatment on the basis that any patient who withdrew from the study because of inadequate symptom control constituted a treatment failure. 12 patients (7 in the FPANS group and 5 in the FPANS plus cetirizine group) withdrew on these grounds. Overall, both treatments were rated as successful for the majority of patients (FPANS 83%, FPANS plus cetirizine 86%).

Withdrawals

67 patients (15%) were withdrawn from the study; 37 from the FPANS group and 30 from the FPANS plus cetirizine group. Some of these patients gave more than one reason for withdrawal, and these may be grouped as follows: adverse events (19 per group), failure to attend or noncompliance (27 in the FPANS group and 11 in the FPANS plus cetirizine group), 'other' reasons (3 in the FPANS group and 6 in the FPANS plus cetirizine group).

Adverse Events

Safety data were collected from the whole of the 8-week treatment period.

A total of 21 patients (5%) reported 22 serious adverse events (12 in the FPANS group and 10 in

the FPANS plus cetirizine group). These events were evenly distributed between the 2 groups (table VI) and, of these, 1 event (drowsiness) in the FPANS group and 4 events (itching/soreness of eyes, epistaxis, exacerbation of rhinitis) in the FPANS plus cetirizine group were judged to be almost certainly related to study medication. A further 6 events in the FPANS group and 2 in the FPANS plus cetirizine group were regarded as either possibly or probably related to study medication.

A total of 295 minor adverse events were reported by 124 patients in the FPANS group (55%), while 286 events were reported by 133 patients in the FPANS plus cetirizine group (59%). The majority of these events were generally associated with the symptoms of seasonal allergic rhinitis. 14 (5%) of these reports in the FPANS group and 17 (6%) in the FPANS plus cetirizine group were considered to be almost certainly related to study treatment. Additionally, a further 40 (14%) in the FPANS group and 54 (19%) in the FPANS plus cetirizine group were considered either probably or possibly related to treatment.

The most frequently reported adverse event was headache, with slightly more headaches being reported by patients in the FPANS group (82 reports) than in the FPANS plus cetirizine group (64 reports; table VII). A comparison of these data with the efficacy data shows that this symptom proved troublesome for a few patients only. There were more reports of tiredness in the FPANS plus cetirizine group (14 reports) than in the FPANS alone group (6 reports).

Discussion

The results of this study show that there is no significant difference in efficacy between FPANS 200µg taken once daily in the morning and FPANS 200µg plus cetirizine 10mg taken once daily in the morning in controlling the symptoms of seasonal allergic rhinitis. Both treatments were effective in preventing symptoms for more than half the time studied and the low overall mean symptom scores showed that the symptoms recorded were gener-

ally mild in severity. Overall assessments by the investigator indicated that treatment had been effective for more than 80% of patients in both groups, and the patients' own global assessment of treatment revealed that for more than 75% of patients in each treatment group, headache and nasal and eye symptoms had been adequately controlled. This is in contrast to a study reported by Drouin et al.,^[14] in which there was an indication of an increased benefit in symptom control using a combination of intranasal corticosteroid and H₂-antagonist. However, it is difficult to compare studies as both the drugs under investigation and methods employed were different to the study reported here.

A combined pollen count was not available for this study, primarily because of the wide variation in counts between rural and suburban centres. However, treatment for this study commenced in mid-May and continued through the months of June and July, a period that coincides with the hayfever season in the UK. Furthermore, the analysis of severity and incidence of symptoms were assessed during the period when, historically, pollen counts are at their highest (weeks 3 to 8).

Patients were free of eye symptoms for approximately 56% of the study period in both treatment groups. This was reflected in the low usage of rescue medication eye drops, which for both treatments were only required for approximately 20% of the study period. Previous reports on the effects of FPANS on ocular symptoms have been contradictory.^[15,16] Dolovich and colleagues^[15] found that eye symptoms were improved with fluticasone propionate compared with placebo, whereas Darnell^[16] found that neither fluticasone propionate nor terfenadine showed any improvement compared with placebo. FPANS is unlikely to have a direct effect on eye symptoms because its action is local, with negligible systemic activity.^[10] Improvements in ocular symptoms following treatment with FPANS probably occur as the result of a retrograde passage of the corticosteroid via the nasolacrimal duct or psychological or reflex effects secondary to the relief of nasal symptoms.^[5]

Nevertheless, the control of ocular symptoms that occurred in this study following treatment with FPANS alone or in combination with the antihistamine, cetirizine, occurred in a population who had found that eye symptoms were the most troublesome symptom they had experienced in the previous hayfever season.

The number of patients who experienced serious adverse events (including those leading to withdrawal of study medication) in the FPANS and FPANS plus cetirizine groups was 5 and 4%, respectively. Minor adverse events were generally associated with the symptoms of seasonal allergic rhinitis, headache being the most commonly reported minor adverse event. When these data were compared with the efficacy data showing the patients were free of headache for approximately 85% of the study period, it was revealed that in fact headache was a troublesome symptom for a few patients only.

Conclusion

In conclusion, this study suggests that there is no significant difference in efficacy between FPANS 200µg taken on its own once daily in the morning, and FPANS 200µg once daily in combination with oral cetirizine 10mg in the prophylactic treatment of seasonal allergic rhinitis.

Acknowledgements

This study was funded by Allen and Hanburys Ltd, Uxbridge, Middlesex, UK.

References

1. Davies R. Seasonal rhinitis in rhinitis mechanisms and management. I Mackay, editor. Royal Society of Medicine 1989: 97-116
2. Sibbald B. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical library. *Thorax* 1991; 46: 895-901
3. Allergy: conventional and alternative concepts. A report of the Royal College of Physicians Committee on Clinical Immunology and Allergy. *Clin Exp Allergy* 1992; 22: Suppl. 3
4. Horak F. Seasonal allergic rhinitis. Newer treatment approaches. *Drugs* 1993; 45 (4): 518-27
5. Bryson HM, Faulds D. Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties

- and therapeutic potential in allergic rhinitis. *Drugs* 1992; 43(5): 760-75
6. Laforce C, Dockhorn R, Findlay S, et al. Fluticasone propionate treatment for seasonal allergic rhinitis is safe and effective in adults and adolescents. Abstract 60. *J Allergy Clin Immunol* 1991; 87 (1: Pt 2): 153
7. Ratner PH, Paull BR, Findlay SR, et al. Fluticasone propionate once daily is as effective as beclomethasone dipropionate twice daily in relieving symptoms of seasonal allergic rhinitis. *Clin Exp Allergy* 1990; 20 Suppl. 1: 98
8. Johannessen TA. A comparison of fluticasone propionate, flunisolide and placebo in patients with seasonal allergic rhinitis to birch pollen - a multi-centre trial. *Clin Exp Allergy* 1990; 20 Suppl. 1: 102
9. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. *JAMA* 1989; 261: 3273-7
10. Harding SM. The human pharmacology of fluticasone propionate. *Respiratory Medicine* 1990; 84 Suppl. A: 25-9
11. Harding SM. Human pharmacology of fluticasone. Abstract no. AS 04. 04. *Allergologie* 1989; 12: 77
12. Davies BH, Mullins J, Couch HA. A comparison of cetirizine (Zirtek) and terfenadine (Triludan). *Clin Trials J* 1989; 26: 100-7
13. Beswick KBJ, Kenyan GS, Cherry JR. A comparative study of beclomethasone aqueous nasal spray with terfenadine tablets in seasonal allergic rhinitis. *Curr Med Res Opin* 1985; 9: 560-7
14. Drouin MA. Is there a benefit to add loratidine to topical nasal steroids in patients with moderately severe seasonal allergic rhinoconjunctivitis? *Allergy* 1992; Suppl. 12 (47): 172
15. Dolovich J, Anderson M, Chodirker W, et al. Fluticasone propionate: a large multi-centre trial. *Respir Med* 1990; 84 Suppl. A: 31-2
16. Darnell R. Multi-centre study of fluticasone propionate aqueous nasal spray and terfenadine tablets in seasonal rhinitis. *Clin Exp Allergy* 1990; 20 Suppl. 1: 101

Correspondence and reprints: Mr C. Benincasa, Allen & Hanburys Ltd, Stockley Park West, Uxbridge, Middlesex UB11 1BT, England.